Literature DB >> 25425239

Economic cost of treatment of childhood epilepsy in Enugu, southeast Nigeria.

Maduka D Ughasoro1, Obinna E Onwujekwe2, Ngozika C Ojinnaka3.   

Abstract

OBJECTIVES: The aim of this study was to determine the economic costs and the level of catastrophic health expenditure (CHE) due to childhood epilepsy.
METHODS: The study was conducted at the Paediatric Neurology Clinic of the University of Nigeria Teaching Hospital, Enugu. Data were collected using pre-tested questionnaires that were administered to caregivers of the children. The indirect and direct expenditure due to childhood epilepsy were computed. A 40 percent of monthly non-food expenditure was used to estimate CHE.
RESULTS: The average annual direct and indirect expenditures were USD 162.6 and USD 82.3, respectively. Most of direct costs were drugs (25.4 percent versus 35.3 percent) and investigations (48.7 percent versus 61.3 percent) for out-patient and in-patient, respectively. CHE was 34.1 percent and 63.6 percent for out-patient and in-patient care, respectively. The total annual costs: (direct and indirect), for childhood epilepsy of USD244.9. Considering the estimated 190,000 epileptic children in Nigeria, it will amount to USD46.53 million annually, approximately 0.018 percent of Nigeria Gross Domestic Product (GDP). All payments were made out-of-pocket with no health insurance for financial risk protection.
CONCLUSIONS: The cost of treatment of childhood epilepsy is high and catastrophic for many households. There was lack of usage of health financial risk mechanisms. Scale-up use of health financial risk protection mechanisms such as health insurance can reduce the economic burden.

Entities:  

Keywords:  Catastrophic health expenditure

Mesh:

Year:  2014        PMID: 25425239     DOI: 10.1017/S0266462314000518

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  6 in total

1.  The economic burden of epilepsy in Bhutan.

Authors:  Leah Wibecan; Günther Fink; Lhab Tshering; Veronica Bruno; Bryan Patenaude; Damber K Nirola; Chencho Dorji; Ugyen Dema; Dillram Pokhrel; Farrah J Mateen
Journal:  Trop Med Int Health       Date:  2018-02-23       Impact factor: 2.622

2.  Impact of poorly controlled epilepsy in the Republic of Guinea.

Authors:  Minyoung Jang; Foksouna Sakadi; Nana R Tassiou; Cissé F Abass; Sara J Grundy; Arcer Woga; Bah A Kenda; Condé M Lamine; Balde A Talibé; Hongxiang Qiu; Joseph M Cohen; Marco Carone; Farrah J Mateen
Journal:  Seizure       Date:  2018-07-24       Impact factor: 3.184

3.  Direct and Indirect Costs of Non-surgical Treatment for Acute Tonsillitis in Children in Southeast Nigeria.

Authors:  Maduka Donatus Ughasoro; James Onuorah Akpeh; Nneamaka Echendu; Somkene Okpala; Nneka Getrude Mgbachi; Ogochukwu Chinelo Okanya; Obinna Emmanuel Onwujekwe
Journal:  Pharmacoecon Open       Date:  2021-04-08

4.  Clinical Application of Epilepsy Genetics in Africa: Is Now the Time?

Authors:  Alina I Esterhuizen; Gemma L Carvill; Rajkumar S Ramesar; Symon M Kariuki; Charles R Newton; Annapurna Poduri; Jo M Wilmshurst
Journal:  Front Neurol       Date:  2018-05-02       Impact factor: 4.003

Review 5.  Understanding variations in catastrophic health expenditure, its underlying determinants and impoverishment in Sub-Saharan African countries: a scoping review.

Authors:  Purity Njagi; Jelena Arsenijevic; Wim Groot
Journal:  Syst Rev       Date:  2018-09-11

6.  Economic burden of the persistent morbidity of nodding syndrome on caregivers in affected households in Northern Uganda.

Authors:  Lugala Samson Yoane Latio; Nguyen Hai Nam; Jaffer Shah; Chris Smith; Kikuko Sakai; Kato Stonewall Shaban; Richard Idro; Nishi Makoto; Nguyen Tien Huy; Shinjiro Hamano; Kazuhiko Moji
Journal:  PLoS One       Date:  2020-09-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.